Sign In
Buy AORT
$20.58
+0.160 (+0.784%)
At Close: Jun 03, 2026
Artivion to Participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference
04:05pm, Tuesday, 04'th Mar 2025
ATLANTA , March 4, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at th
Down -18.58% in 4 Weeks, Here's Why Artivion (AORT) Looks Ripe for a Turnaround
10:35am, Thursday, 27'th Feb 2025
Artivion (AORT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising
Artivion, Inc. (AORT) Q4 2024 Earnings Call Transcript
11:00pm, Monday, 24'th Feb 2025
Artivion, Inc. (NYSE:AORT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - C
Artivion (AORT) Reports Break-Even Earnings for Q4
06:21pm, Monday, 24'th Feb 2025
Artivion (AORT) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.12. This compares to earnings of $0.11 per share a year ago.
Artivion Reports Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Monday, 24'th Feb 2025
Fourth Quarter Highlights: Achieved revenue of $97.3 million in the fourth quarter of 2024 versus $93.7 million in the fourth quarter of 2023, an increase of 4% on a GAAP basis and 3% on a non-GAAP co
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2024 Financial Results
04:10pm, Monday, 10'th Feb 2025
ATLANTA , Feb. 10, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and full year 2024 f
On The Hunt For Magnificent Earnings Growth? Check These 7 Stocks.
03:09pm, Monday, 03'rd Feb 2025
None of our picks is Nvidia or Amazon or Tesla. Investors may wish to widen the aperture to find the best stocks for outsize earnings growth.
Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion ATLANTA , Jan. 27, 2025 /PRNewswire/ -- Artivion, I
Best Momentum Stocks to Buy for January 7th
11:25am, Tuesday, 07'th Jan 2025
NN, VERX and AORT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 7, 2024.
New Strong Buy Stocks for January 7th
08:21am, Tuesday, 07'th Jan 2025
AORT, VERX, NN, IMCR and EVER have been added to the Zacks Rank #1 (Strong Buy) List on January 7, 2024.
US medical device giant Artivion says hackers stole files during cybersecurity incident
10:52am, Monday, 09'th Dec 2024
Artivion, a medical device company that manufactures implantable tissues for cardiac and vascular transplant applications, says its services have been “disrupted” due to a cybersecurity incident.
Artivion Granted FDA Humanitarian Device Exemption for the AMDS Hybrid Prosthesis
08:00am, Monday, 09'th Dec 2024
ATLANTA , Dec. 9, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration
Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript
12:02pm, Saturday, 09'th Nov 2024
Artivion, Inc. (NYSE:AORT ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Dorothy Morgan - Gilmartin Group LLC Pat Mackin - Chief Executive Officer Lance Berry - Ch
Artivion (AORT) Tops Q3 Earnings and Revenue Estimates
07:10pm, Thursday, 07'th Nov 2024
Artivion (AORT) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.02 per share a year ago.
Artivion Reports Third Quarter 2024 Financial Results
04:05pm, Thursday, 07'th Nov 2024
Third Quarter Highlights: Achieved revenue of $95.8 million in the third quarter of 2024 versus $87.9 million in the third quarter of 2023, an increase of 9% on a GAAP basis and 10% on a non-GAAP cons
